Seigo Katakura on Muck Rack

Seigo Katakura

As seen in: Wiley Online Library, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Seigo

Contact Seigo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study

|
By Shuji Murakami, Yukihiko Hiroshima, Seigo Katakura
| Wiley Online Library Verified
ALK anaplastic lymphoma kinase CGP comprehensive genomic profile CI confidence intervals EGFR epidermal growth factor receptor EP expert panel MET mesenchymal epithelial transition NGS next-generation sequencing NSCLC non-small cell lung cancer NTRK neurotrophic tyrosine receptor kinase ODxTT Oncomine Dx Target Test PR partial response SD stable disease 1 Introduction In clinical practice, the identification of genomic alterations is essential before making treatment decisions for patients...
Open in Who Shared Issue with article?

Investigating EMT-mediated resistance to EGFR tyrosine kinase inhibitors in NSCLC using innovative organoid models

|
By Nobuaki Kobayashi, Seigo Katakura, Nobuhiko Fukuda, Shuhei Teranishi
| biorxiv.org
Abstract Background: Epithelial-mesenchymal transition (EMT) has emerged as a key mechanism underlying resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). However, the intricacies of EMT-mediated resistance, driven by tumor microenvironment (TME) interactions, remain enigmatic. This study aimed to probe EMT-induced resistance in NSCLC using innovative in vitro organoid models.
Open in Who Shared Issue with article?

Combination treatment options for small-cell lung cancer

|
By Nobuyuki Horita, Kaneko Takeshi, Seigo Katakura
| The Lancet Verified
1 Goldman JW Dvorkin M Chen Y et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021; 1 : 51-65 regarding the updated data from the CASPIAN trial.
Open in Who Shared View Duplicates (2) Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified